Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL61 | 0.91 | AGTR1 (0.59) | AGTR1AGTR2 | |
| SCHEMBL7998832 | 0.90 | AGTR1 (0.63) | AGTR1AGTR2 | |
| SCHEMBL8469323 | 0.90 | AGTR1 (0.46) | AGTR1AGTR2 | |
| SCHEMBL6536653 | 0.90 | AGTR1 (0.57) | AGTR1AGTR2 | |
| SCHEMBL9207303 | 0.90 | AGTR1 (0.46) | AGTR1AGTR2 | |
| SCHEMBL8514398 | 0.88 | AGTR1 (0.56) | AGTR1AGTR2 | |
| SCHEMBL7171699 | 0.88 | AGTR1 (0.57) | AGTR1AGTR2 | |
| SCHEMBL5138819 | 0.88 | AGTR1 (0.64) | AGTR1AGTR2 | |
| SCHEMBL9328849 | 0.87 | AGTR1 (0.64) | AGTR1AGTR2 | |
| SCHEMBL28491030 | 0.86 | AGTR1 (0.55) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6576652-B2 | Administering substituted imidazoles, particular by losartan potassium, treatment of post-transplant hypertension. | MERCK SHARP & DOHME (ITALIA) S.P.A. (IT) | 2003-06-10 | — | — | US | claimed |
| US-20020115702-A1 | Use of an angiotensin II receptor antagonist for the preparation of drugs to increase the survival rate of renal transplant patients | MERCK SHARP & DOHME (ITALIA) S.P.A. (IT) | 2002-08-22 | — | — | US | claimed |
| US-6300356-B1 | ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT A THERAPEUTICALLY EFFECTIVE AMOUNT OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST | MERCK & CO., INC. | 2001-10-09 | — | — | US | claimed |
| US-6201002-B1 | ADMINISTERING IMIDAZOLE DERIVATIVE TO TREAT CONGESTIVE HEART FAILURE AND CARDIOVASCULAR DISORDERS | MERCK & CO., INC. | 2001-03-13 | — | — | US | claimed |
| EP-1059843-A1 | METHOD FOR DECREASING QT DISPERSION OR INHIBITING THE PROGRESSION OF QT DISPERSION WITH AN ANGIOTENSIN II RECEPTOR ANTAGONIST | Merck & Co., Inc. (US) | 2000-12-20 | — | — | EP | claimed |
| JP-2000508347-A | — | — | 2000-07-04 | — | — | JP | claimed |
| EP-0966282-A1 | USE OF ANGIOTENSIN II ANTAGONISTS TO TREAT SYMPTOMATIC HEART FAILURE | Merck & Co., Inc. (US) | 1999-12-29 | — | — | EP | claimed |
| WO-1999043210-A1 | METHOD FOR DECREASING QT DISPERSION OR INHIBITING THE PROGRESSION OF QT DISPERSION WITH AN ANGIOTENSIN II RECEPTOR ANTAGONIST | MERCK & CO., INC. (US) | 1999-09-02 | — | — | WO | claimed |
| WO-1998030216-A1 | USE OF ANGIOTENSIN II ANTAGONISTS TO TREAT SYMPTOMATIC HEART FAILURE | MERCK & CO., INC. (US) | 1998-07-16 | — | — | WO | claimed |
| WO-1995026724-A1 | IMPROVEMENT OF INSULIN SENSITIVITY WITH ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES | EIDE IVAR KONRAD (NO) | 1995-10-12 | — | — | WO | claimed |
| WO-1989006233-A1 | ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES AND COMBINATIONS THEREOF WITH DIURETICS AND NSAIDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-13 | — | — | WO | claimed |
| EP-0754042-A4 | TREATMENT OF ATHEROSCLEROSIS WITH ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES | MERCK & CO INC (US) | 2004-06-23 | — | — | EP | disclosed |
| US-6576652-B2 | Administering substituted imidazoles, particular by losartan potassium, treatment of post-transplant hypertension. | MERCK SHARP & DOHME (ITALIA) S.P.A. (IT) | 2003-06-10 | — | — | US | disclosed |
| US-20020115702-A1 | Use of an angiotensin II receptor antagonist for the preparation of drugs to increase the survival rate of renal transplant patients | MERCK SHARP & DOHME (ITALIA) S.P.A. (IT) | 2002-08-22 | — | — | US | disclosed |
| US-6300356-B1 | ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT A THERAPEUTICALLY EFFECTIVE AMOUNT OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST | MERCK & CO., INC. | 2001-10-09 | — | — | US | disclosed |
| WO-1999043210-A1 | METHOD FOR DECREASING QT DISPERSION OR INHIBITING THE PROGRESSION OF QT DISPERSION WITH AN ANGIOTENSIN II RECEPTOR ANTAGONIST | MERCK & CO., INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| US-5663186-A | TREATING ATHEROSCLEROSIS AND REDUCING CHOLESTEROL ALONE OR IN CONJUCTION WITH THE TREATMENT OF HYPERTENSION USING A MIXTURE OF LOSARTAN, SIMVASTATIN AND ENALPRIL | MERCK & CO., INC. (US) | 1997-09-02 | — | — | US | disclosed |
| EP-0754042-A1 | TREATMENT OF ATHEROSCLEROSIS WITH ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES | MERCK & CO. INC. (US) | 1997-01-22 | — | — | EP | disclosed |
| WO-1995026724-A1 | IMPROVEMENT OF INSULIN SENSITIVITY WITH ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES | EIDE IVAR KONRAD (NO) | 1995-10-12 | — | — | WO | disclosed |
| WO-1995026188-A1 | TREATMENT OF ATHEROSCLEROSIS WITH ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES | MERCK & CO., INC. (US) | 1995-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115702-A1 | Use of an angiotensin II receptor antagonist for the preparation of drugs to increase the survival rate of renal transplant patients | AGTR2, AGTR1, REN | AGTR1 2/4885AGTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.